AI assistant
Sending…
Esperion Therapeutics, Inc. — Director's Dealing 2023
Mar 8, 2023
32771_dirs_2023-03-08_4094e755-3ee0-4cdf-aec0-875db5ce3be6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2023-03-07
Reporting Person: Warren Eric (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-07 | Common Stock | S | 5090 | $5.055 | Disposed | 48572 | Direct |
Footnotes
F1: Shares were sold to satisfy tax obligation on vested shares of performance-based restricted stock units.
More from Esperion Therapeutics, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 1
Interim / Quarterly Report
2026
May 8
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 3
Director's Dealing
2026
Jan 21